 Thalidomide
"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
| Descriptor ID |
D013792
|
| MeSH Number(s) |
D02.241.223.805.810.800 D03.383.621.808.800 D03.438.513.750.750
|
| Concept/Terms |
Thalomid- Thalomid
- Celgene Brand of Thalidomide
|
Below are MeSH descriptors whose meaning is more general than "Thalidomide".
Below are MeSH descriptors whose meaning is more specific than "Thalidomide".
This graph shows the total number of publications written about "Thalidomide" by people in UAMS Profiles by year, and whether "Thalidomide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 4 | 4 | | 2022 | 0 | 1 | 1 | | 2021 | 1 | 1 | 2 | | 2020 | 1 | 5 | 6 | | 2019 | 2 | 8 | 10 | | 2018 | 1 | 3 | 4 | | 2017 | 4 | 2 | 6 | | 2016 | 11 | 6 | 17 | | 2015 | 4 | 3 | 7 | | 2014 | 8 | 4 | 12 | | 2013 | 6 | 7 | 13 | | 2012 | 4 | 6 | 10 | | 2011 | 7 | 6 | 13 | | 2010 | 7 | 5 | 12 | | 2009 | 3 | 1 | 4 | | 2008 | 7 | 6 | 13 | | 2007 | 1 | 7 | 8 | | 2006 | 4 | 1 | 5 | | 2005 | 2 | 3 | 5 | | 2004 | 5 | 3 | 8 | | 2003 | 2 | 3 | 5 | | 2002 | 6 | 3 | 9 | | 2001 | 3 | 1 | 4 | | 2000 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Thalidomide" by people in Profiles over the past ten years.
-
Strouse C, Mott SL, Smith BJ, Magalhaes-Silverman M, Farooq U, Zhan F, Jethava Y, Tricot G. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients. Bone Marrow Transplant. 2024 01; 59(1):128-130.
-
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Davies FE, Leleu X, Vogel P, Dhanasiri S, Le Nouveau P, Weisel K. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):829-837.e1.
-
Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant. 2023 08; 58(8):953-955.
-
Wang JN, Liu T, Zhao AL, Pan BJ, Sun J, Li J, Zhou DB, Cao XX, Duan MH. Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis. Leukemia. 2022 06; 36(6):1619-1624.
-
Wei C, Zhou DB. Long-time remission of laryngeal Rosai-Dorfman disease with thalidomide: a report of three cases. Hematology. 2021 Dec; 26(1):552-555.
-
Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 12; 35(12):3526-3533.
-
Ainley L, Chavda SJ, Counsell N, Cheesman S, Newrick F, Horder J, Kyriakou C, Papanikolaou X, Sive J, Lee L, Wechalekar A, Mehta A, Popat R, Rabin N, Yong K. DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. Br J Haematol. 2021 02; 192(3):e73-e77.
-
Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, Shune L, McGuirk J, Ganguly S. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):e212-e219.
-
Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood. 2020 08 27; 136(9):1091-1104.
-
Lyzogubov V, Dasso M, Bora N, Bora PS. Role of thalidomide, senicapoc, and sodium butyrate in choroidal neovascularization. Biochem Biophys Res Commun. 2020 09 17; 530(2):367-373.
-
Jackson GH, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Wilson J, Taylor C, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Drayson MT, Kaiser MF, Owen RG, Gregory WM, Davies FE, Morgan GJ. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. Br J Haematol. 2021 03; 192(5):853-868.
-
Zhou X, Steinhardt MJ, Grathwohl D, Meckel K, Nickel K, Leicht HB, Krummenast F, Einsele H, Rasche L, Kort?m KM. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. Cancer Med. 2020 08; 9(16):5819-5826.
-
Zhang X, Thummuri D, He Y, Liu X, Zhang P, Zhou D, Zheng G. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem Commun (Camb). 2019 Dec 05; 55(98):14765-14768.
-
Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Vi? MD, Sanchez R, Bruins L, Demler T, M?ller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, St?hmer T, Kort?m KM. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020 05; 105(5):e237-e241.
-
Patil A, Manzano M, Gottwein E. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma. Blood Adv. 2019 07 23; 3(14):2105-2117.
-
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep; 6(9):e459-e469.
-
Shah J, Usmani S, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):570-578.e1.
-
van Rhee F, Stone K. Storming the Castle with TCP. Blood. 2019 04 18; 133(16):1697-1698.
-
Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 07 11; 134(2):123-133.
-
Huang YH, Zhou DB, Han B, Li T, Wang SJ. Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone. J Int Med Res. 2019 Apr; 47(4):1810-1814.
-
Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, Zhou DB, Zhong DR, Fajgenbaum DC, Li J. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019 04 18; 133(16):1720-1728.
-
Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica. 2019 07; 104(7):1440-1450.
-
Hussain MJ, Robinson MM, Hamadeh I, Arnall J, Bhutani M, Atrash S, Friend R, Pineda-Roman M, Symanowski JT, Usmani SZ, Voorhees PM. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma. Br J Haematol. 2019 07; 186(1):140-144.
-
Arnall JR, Usmani SZ, Adamu H, Mishkin J, Bhutani M. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement. J Oncol Pharm Pract. 2019 Jun; 25(4):1021-1025.
-
Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, Drayson MT, Davies FE, Jackson GH, Morgan GJ, Child JA. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br J Haematol. 2018 09; 182(6):816-829.
-
Patil A, Manzano M, Gottwein E. CK1a and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018 08 09; 132(6):577-586.
-
Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematol. 2017 Dec; 4(12):e584-e594.
-
Ward RM, Benjamin DK, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CMT. The Need for Pediatric Drug Development. J Pediatr. 2018 01; 192:13-21.
-
Zhang X, Cai QQ, Huang XF, Cao XX, Cai H, Zhou DB, Dai RP, Li J. OCULAR MANIFESTATIONS AND TREATMENT OUTCOMES IN CHINESE PATIENTS WITH POEMS SYNDROME. Retina. 2017 Sep; 37(9):1784-1791.
-
Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Neutral tumor evolution in myeloma is associated with poor prognosis. Blood. 2017 10 05; 130(14):1639-1643.
-
de Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE, Colleoni GWB. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017 09 10; 403:206-215.
-
Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 09 07; 130(10):1189-1197.
-
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 02 04; 389(10068):519-527.
-
Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016 12 09; 6(12):e506.
-
Hinduja A, Limaye K, Ravilla R, Sasapu A, Papanikolaou X, Wei L, Torbey M, Waheed S. Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. PLoS One. 2016; 11(11):e0166627.
-
Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ. Practical Considerations in Managing Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 02; 17(2):69-77.
-
Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res. 2017 Jun 01; 23(11):2665-2672.
-
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 10 06; 375(14):1319-1331.
-
Usmani SZ. Maintenance lenalidomide after transplantation: How much is enough? Cancer. 2016 12 15; 122(24):3762-3764.
-
Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood Cancer J. 2016 07 29; 6(7):e453.
-
Sriskandarajah P, Pawlyn C, Mohammed K, Dearden CE, Davies FE, Morgan GJ, Boyd KD, Kaiser MF. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leuk Lymphoma. 2017 02; 58(2):494-497.
-
Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, R?llig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 07 28; 128(4):497-503.
-
Cao XX, Wang T, Liu YH, Zhou DB, Li J. Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy. Leuk Lymphoma. 2016 12; 57(12):2934-2936.
-
Wang C, Guan YZ, Cai QQ, Su W, Zhou DB, Li J. Rapidly Progressive Polyneuropathy in a Patient With Monoclonal Gammopathy: A Case Report of POEMS Syndrome and Beyond. Medicine (Baltimore). 2016 Apr; 95(16):e3453.
-
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blad? J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; 127(24):2955-62.
-
Jones JR, Pawlyn C, Davies FE, Morgan GJ. The safety of pomalidomide for the treatment of multiple myeloma. Expert Opin Drug Saf. 2016; 15(4):535-47.
-
Gao M, Kong Y, Wang H, Xie B, Yang G, Gao L, Zhang Y, Zhan F, Dai B, Tao Y, Shi J. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol. 2016 Aug; 37(8):11081-98.
-
Du X, Jin J, Cai Z, Chen F, Zhou DB, Yu L, Ke X, Li X, Wu D, Meng F, DeMarco D, Zhang J, Mei J, Hou J. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. BMC Cancer. 2016 Jan 28; 16:46.
-
Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, Garc?a-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016 Apr 14; 127(15):1896-906.
-
Usmani SZ, Cavenagh JD, Belch AR, Hulin C, Basu S, White D, Nooka A, Ervin-Haynes A, Yiu W, Nagarwala Y, Berger A, Pelligra CG, Guo S, Binder G, Gibson CJ, Facon T. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016; 19(3):243-58.
-
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015 Aug 07; 5:e334.
-
Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. Br J Haematol. 2015 Aug; 170(3):336-48.
-
Arikian SR, Milentijevic D, Binder G, Gibson CJ, Hu XH, Nagarwala Y, Hussein M, Corvino FA, Surinach A, Usmani SZ. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015 Jun; 31(6):1105-15.
-
Zhou DB, Yu L, Du X, Jin J, Cai Z, Chen F, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, DeMarco D, Chen N, Mei J, Wang J, Hou J. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int J Hematol. 2015 Jun; 101(6):569-77.
-
Cai QQ, Wang C, Cao XX, Cai H, Zhou DB, Li J. Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. Eur J Haematol. 2015 Oct; 95(4):325-30.
-
Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transplant. 2015 May; 50(5):673-8.
-
Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, Dimopoulos MA. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. Br J Haematol. 2015 Mar; 168(6):820-3.
-
Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, Morgan GJ, Andreyev HJ. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014 Oct 09; 124(15):2467-8.
-
Usmani SZ, Lonial S. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S71-7.
-
Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B. Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma. Leukemia. 2014 Dec; 28(12):2413-5.
-
Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, Xu H, Zhan F, Shi J. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol. 2014; 7(6):3073-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|